Today: 17 January 2026
Subscribe
Browse Category

Medical Technology News 29 July 2025 - 22 October 2025

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific (NYSE:BSX) posted reported net income of $755 M ($0.51/share GAAP) and adjusted EPS of $0.75 Timesunion Chartmill, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” Prnewswire, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year…
22 October 2025
····
Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical’s da Vinci surgical robot in an operating room setting. Intuitive’s stock jumped on Oct. 21 after the company reported blowout Q3 results and raised full-year guidance Reuters ts2.tech. The quarter’s 23% revenue growth was driven by a surge in robot-assisted procedures, as hospitals resume elective surgeries and expand minimally-invasive care Reuters Reuters. Reuters notes Intuitive has seen “steady…
22 October 2025
····
Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 Investing Marketbeat. Over the past year, the price swung between about $425 and $616 Investing. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector,…
19 October 2025
····
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings Stocktitan. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis Stocktitan. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result”…
9 October 2025
···
MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

Ottobock’s Blockbuster Debut in Frankfurt Ottobock’s IPO made headlines as the prosthetics manufacturer delivered a much-needed jolt to Germany’s capital market. Trading in Ottobock shares began on October 9, 2025, on the Frankfurt Stock Exchange’s Prime Standard segment. The stock’s first trade at €72.00 was significantly above the €66 per share offering price Deutsche Boerse. That opening price equated to about a +9% “pop” for…
9 October 2025
····
AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

A boy in the United States with three years of chronic pain was diagnosed by an AI chatbot with spina bifida occulta, later confirmed by a specialist. Microsoft’s AI Diagnostic Orchestrator (MAI-DxO) achieved an 85% correct diagnosis rate on nearly 300 challenging NEJM case studies, compared with 20% for 21 experienced physicians, while ordering 20% fewer tests. Google’s conversational diagnostic…
29 July 2025
1 2 3 4

Stock Market Today

  • Moog (MOG.A) Valuation Appears Fair After DCF Check, But Upside Limited
    January 17, 2026, 2:06 PM EST. Moog Inc. trades near $291 after a strong multi-year run, with 6.7% weekly, 19.3% over 30 days, and 292.9% over five years. A Simply Wall St valuation pack gives Moog a 3/6 value score, reflecting mixed signals from different methods. A 2-stage Discounted Cash Flow (DCF) model pegs intrinsic value at about $299.78 per share, versus the $290.80 close, implying roughly a 3% discount and a fair value stance. The model uses Free Cash Flow to Equity (FCFE), with trailing FCF around $103.6 million and forecasts to 2027 of $273.8 million; projections extend to 2035. P/E remains a quick lens on price vs. earnings, but growth and risk shift the balance. In short, Moog looks fairly valued, but near-term catalysts matter.
Go toTop